Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging. Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma. Design: A systematic revi...

Full description

Bibliographic Details

Published in:	European Clinical Respiratory Journal
Main Authors:	Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise Klokker Madsen, Bo L. Chawes
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-01-01
Subjects:	Severe asthma anti-IL-5 reslizumab mepolizumab systematic review
Online Access:	http://dx.doi.org/10.1080/20018525.2018.1536097